You appear to be using incognito/private browsing mode or an ad blocker, which may adversely affect your experience on the site. Please disable any ad blockers and view the site in non-private mode.
Wrong country/market login message
Fast, easy and reliably accurate
When there is a pressing need for a diagnosis and a treatment decision, patients rely on you and your staff for the most responsive, trustworthy medical attention available.
The cobas Liat PCR System allows you to detect and identify SARS-CoV-21, SARS-CoV-2 & Influenza A/B1, Influenza A/B & RSV, Group A Strep, and C. Difficile2 — in your own clinic, using gold-standard PCR technology previously available only in complex molecular laboratories.
The cobas Liat PCR System is small, easy to use and fast—able to provide accurate results by the end of a patient’s appointment.
The cobas Liat System is on-site molecular testing you can depend on. For the patients who depend on you.
With real-time PCR technology
No need for interpretation.
3 easy steps; 15 to 20 minutes, depending on the assay.
. . . now at physicians' fingertips
Roche has pioneered the advancement of polymerase chain reaction (PCR) analysis, now recognized as a gold standard in laboratory diagnostics.
Recognized as one of the most important scientific advances of the 20th century1, polymerase chain reaction (PCR) is a quick, easy way to create unlimited copies of DNA or RNA from just one original strand.
1. Mark R. Hughes, deputy director of the National Center for Human Genome Research at the National Institutes of Health (perhaps better known as the Human Genome Project).
In large molecular laboratories, PCR analysis can be performed on many samples simultaneously—a multi-step process requiring a skilled technician.
The cobas Liat System fully automates these steps for the rapid analysis of a single sample, making it ideal for time-sensitive in-office diagnoses.
No operator intervention or interpretation required.
Technical Specifications
View Full TableTechnical Specifications
| Power supply |
|
|---|---|
| Input | 100-240V AC /50-60Hz |
| Output | 15V DC / 8.6A |
| Environmental requirements (operating) |
|
| Temperature | +15°C to +32°C |
| Relative humidity | 15% to 80% (non-condensing) |
| Maximum altitude | 2,000 m (6,500 ft.) above sea level |
| Dimensions and weight |
|
| Height | 19.0 cm (7.5") |
| Width | 11.4 cm (4.5") |
| Length | 24.1 cm (9.5") |
| Weight | 3.76 kg (8.3 lbs.) |
| Data and display |
|
| Up to 20,000 records can be stored, backed up and archived | |
| HL7 enabled connectivity | |
| Barcode types supported |
|
| Codabar |
|
| Code 39 | |
| Code 93 | |
| Code 128 |
|
| EAN-8 |
|
| EAN-13 | |
| GS1-DataBar |
|
| Interleaved 2 of 5 |
|
| Ordering information |
|
| cobas® Liat Analyzer | 07341920190 |
| cobas® SARS CoV-21 | 09211101190 |
| cobas® SARS CoV-2 & Influenza A/B1 | 09408592190 |
| cobas® Strep A | 07341911190 |
| cobas® Influenza A/B & RSV | 08160104190 |
| cobas® C. Difficile2 | 07454945190 |
With a broad menu of assays in development and the long-term commitment of Roche Molecular Diagnostics, the cobas Liat System can help you respond to time-sensitive patient care needs.
SARS-CoV-21
View Full TableSARS-CoV-21
For use with screening symptomatic and asymptomatic patients
| SARS-CoV-21 assay performance | |||
|---|---|---|---|
| Positive Agreement | Negative Agreement | LoD | |
| Symptomatic Individuals | 96.1% | 96.8% | 2.4 x 10-2 TCID50/mL (24 copies/mL) |
| Asymptomatic Individuals | 100% | 98.9% | 1.2 x 10-2 TCID50/mL |
SARS-CoV-2 & Influenza A/B1
View Full TableSARS-CoV-2 & Influenza A/B1
For use with symptomatic and asymptomatic patients
| SARS-CoV-2 & Influenza A/B1 assay performance | |||
|---|---|---|---|
| Positive Agreement | Negative Agreement | LoD | |
| SARS | 100% | 100% | 1 x 10-2 TCID50/mL (12 copies/mL) |
| Flu A | 98.4% | 96.5% | 2 x 10-3 – 2 x 10-2 TCID50/mL |
| Flu B | 97.9% | 99.4% | 2 x 10-3 – 4 x 10-3 TCID50/mL |
Strep A
View Full TableStrep A
Accurate results, no confirmation needed
| cobas® Strep A Assay Performance |
||
|---|---|---|
| Sensitivity | Specificity | LoD |
| 98.3% | 94.2% | 5–20 CFU/mL |
Influenza A/B & RSV
View Full TableInfluenza A/B & RSV
1 sample, 1 test, 3 results and 0 age restrictions
| cobas® Influenza A/B & RSV Assay Performance |
||
|---|---|---|
| Positive Agreement | Negative Agreement | |
| Influenza A | 98.3% | 96.0% |
| Influenza B | 95.2% | 99.4% |
| RSV | 97.0%* | 98.7% |
C. Difficile2
View Full TableC. Difficile2
Accurate results, no confirmation needed
| C. Difficile2 Assay Performance | ||
|---|---|---|
| Sensitivity vs. direct culture | Specificity vs. culture | LoD |
| 94.6% | 96.2% | 90 CFU/swab |
